Cargando…

In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing Klebsiella pneumoniae: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations

Ceftazidime/avibactam uniquely demonstrates activity against both KPC and OXA-48-like carbapenemase-expressing Enterobacterales. Clinical resistance to ceftazidime/avibactam in KPC-producers was foreseen in in-vitro resistance studies. Herein, we assessed the resistance selection propensity of cefta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Palwe, Snehal, Bakthavatchalam, Yamuna Devi, Khobragadea, Kshama, Kharat, Arun S., Walia, Kamini, Veeraraghavan, Balaji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8614831/ https://www.ncbi.nlm.nih.gov/pubmed/34827256 http://dx.doi.org/10.3390/antibiotics10111318

Ejemplares similares

In Vitro Activities of Ceftazidime–Avibactam and Aztreonam–Avibactam at Different Inoculum Sizes of Extended-Spectrum β-Lactam-Resistant Enterobacterales Blood Isolates
por: Bae, Moonsuk, et al.
Publicado: (2021)

Loss of exclusivity of ceftazidime/avibactam in low- and middle-income countries: a test for antibiotic stewardship practice
por: Veeraraghavan, Balaji, et al.
Publicado: (2023)

Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa
por: Brink, Adrian J., et al.
Publicado: (2022)

The Effect of β-Lactam Antibiotics on the Evolution of Ceftazidime/Avibactam and Cefiderocol Resistance in KPC-Producing Klebsiella pneumoniae
por: Zhang, Ping, et al.
Publicado: (2023)

Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria
por: Gonzalez, Mark D., et al.
Publicado: (2017)

β-Lactam Resistance in ESKAPE Pathogens Mediated Through Modifications in Penicillin-Binding Proteins: An Overview
por: Sethuvel, Dhiviya Prabaa Muthuirulandi, et al.
Publicado: (2023)

OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs
por: Fröhlich, Christopher, et al.
Publicado: (2019)

Pharmacokinetics of Non-β-Lactam β-Lactamase Inhibitors
por: Luci, Giacomo, et al.
Publicado: (2021)

In vitro potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing Enterobacterales
por: Lomovskaya, Olga, et al.
Publicado: (2023)

In Vitro Activity of β-Lactams in Combination with β-Lactamase Inhibitors against Mycobacterium tuberculosis Clinical Isolates
por: Li, Fu, et al.
Publicado: (2018)

In vitro activity of new combinations of β-lactam and β-lactamase inhibitors against the Mycobacterium tuberculosis complex
por: Economou Lundeberg, Elin, et al.
Publicado: (2023)

Interactions between Avibactam and Ceftazidime-Hydrolyzing Class D β-Lactamases
por: Frère, Jean-Marie, et al.
Publicado: (2020)

An NDM-Producing Escherichia coli Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-β-Lactam Resistance
por: Simner, Patricia J, et al.
Publicado: (2023)

β-Lactam Antibiotics Renaissance
por: Qin, Wenling, et al.
Publicado: (2014)

β-Lactam Allergy in Children
por: Suleyman, Ayse, et al.
Publicado: (2021)

β-Lactams from the Ocean
por: Fisher, Jed F., et al.
Publicado: (2023)

Genomic Characterization of KPC-31 and OXA-181 Klebsiella pneumoniae Resistant to New Generation of β-Lactam/β-Lactamase Inhibitor Combinations
por: Muresu, Narcisa, et al.
Publicado: (2022)

Effect of β-Lactamase inhibitors on in vitro activity of β-Lactam antibiotics against Burkholderia cepacia complex species
por: Everaert, Annelien, et al.
Publicado: (2016)

In Vitro and In Vivo Development of a β-Lactam-Metallo-β-Lactamase Inhibitor: Targeting Carbapenem-Resistant Enterobacterales
por: Peters, Byron K., et al.
Publicado: (2023)

1795. Safety Outcomes of the Use of β-Lactam Therapy in Patients With Documented β-Lactam Allergy
por: Bjork, Lauren
Publicado: (2018)

Outer membrane vesicles from β-lactam-resistant Escherichia coli enable the survival of β-lactam-susceptible E. coli in the presence of β-lactam antibiotics
por: Kim, Si Won, et al.
Publicado: (2018)

Comparative in vitro Activities of Ceftazidime–Avibactam and Ceftolozane-tazobactam Against Characterized β-Lactamase-producing Pseudomonas aeruginosa
por: Lin, Lynn-Yao, et al.
Publicado: (2017)

BADAN-conjugated β-lactamases as biosensors for β-lactam antibiotic detection
por: Au, Ho-Wah, et al.
Publicado: (2020)

Cryptic β-Lactamase Evolution Is Driven by Low β-Lactam Concentrations
por: Fröhlich, Christopher, et al.
Publicado: (2021)

Repurposing β-Lactams for the Treatment of Mycobacterium kansasii Infections: An In Vitro Study
por: Muñoz-Muñoz, Lara, et al.
Publicado: (2023)

1593. Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Against OXA-48 β-lactamase–Producing Enterobacterales Collected in International Medical Centers, Including the United States, in 2017–2018
por: Lin, Lynn-Yao, et al.
Publicado: (2020)

Chemiluminescence Detection of Hydrogen Sulfide Release by β-Lactamase-Catalyzed β-Lactam Biodegradation: Unprecedented Pathway for Monitoring β-Lactam Antibiotic Bacterial Resistance
por: Gholap, Sachin Popat, et al.
Publicado: (2021)

1299. In Vitro-In Vivo Discordance with β-lactams against Metallo-β-lactamase-Producing Enterobacterales: Implications for Susceptibility Testing
por: Abdelraouf, Kamilia, et al.
Publicado: (2020)

In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan
por: Yang, Tsung-Ying, et al.
Publicado: (2020)

In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors
por: Shields, Ryan K, et al.
Publicado: (2023)

P10 Ceftazidime/avibactam for OXA-48 urinary tract infections—a 12 month remissive study
por: Fernandes, Afonso Paes, et al.
Publicado: (2023)

The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations
por: Aslan, Abdullah Tarık, et al.
Publicado: (2022)

Time-resolved β-lactam cleavage by L1 metallo-β-lactamase
por: Wilamowski, M., et al.
Publicado: (2022)

Synthesis and biological evaluation of novel β-lactam-metallo β-lactamase inhibitors
por: Shungube, Mbongeni, et al.
Publicado: (2023)

Accuracy in diagnosis of allergy to β-lactams
por: Iglesias-Souto, Javier, et al.
Publicado: (2012)

Regulation and compartmentalization of β‐lactam biosynthesis
por: Martín, Juan F., et al.
Publicado: (2010)

Occupational allergy to β-lactam antibiotics
por: Classen, Anna, et al.
Publicado: (2015)

Optimizing β-Lactams against Tuberculosis
por: de Jager, Veronique R., et al.
Publicado: (2020)

Hypersensitivity to non-β-lactam antibiotics
por: Merk, Hans F., et al.
Publicado: (2022)

Antipseudomonal β-Lactams Resistance in Iran
por: Rabiei, Mohammad Mahdi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6nndks2tndc8gtiaf916nfvjb1